Taysha Gene Therapies, Inc.

TSHA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$89-$112-$166-$175
Dep. & Amort.$1$1$1$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$13$8$18$18
Change in WC-$12-$18$19$29
Other Non-Cash$6$47$40$10
Operating Cash Flow-$81-$73-$88-$117
Investing Activities
PP&E Inv.-$0-$4-$25-$22
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0-$3-$0$0
Investing Cash Flow-$0-$7-$25-$22
Financing Activities
Debt Repay.$0-$3$0$40
Stock Issued$77$141$53-$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$0-$1-$1-$1
Financing Cash Flow$77$136$52$39
Forex Effect$0$0$0$0
Net Chg. in Cash-$5$56-$61-$100
Supplemental Information
Beg. Cash$147$91$152$251
End Cash$142$147$91$152
Free Cash Flow-$82-$80-$113-$139
Taysha Gene Therapies, Inc. (TSHA) Financial Statements & Key Stats | AlphaPilot